Preclinical study suggests ARID1a may be useful biomarker for immunotherapy – Medical Xpress
Medical Xpress |
Preclinical study suggests ARID1a may be useful biomarker for immunotherapy
Medical Xpress Treatment with the checkpoint blockade therapy significantly improved survival in mice with ARID1a mutations, suggesting immunotherapy could be useful for patients with ARID1a-mutant tumors. "Our findings link ARID1a mutations to MMR deficiency, thus … |
